The PARP Inhibitors market size is anticipated to increase in the study period due to a direct consequence of an increase in R&D activity in the 7MM. Additionally, the competitive landscape is relatively sparse and the regulatory pathway for approval will likely involve extensive clinical trials to demonstrate safety and efficacy.
DelveInsight’s PARP Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging PARP Inhibitors, market share of individual therapies, and current and forecasted PARP Inhibitors market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the PARP Inhibitors Market Report
- As per DelveInsight’s analysis, the PARP Inhibitors market is anticipated to grow at a significant CAGR by 2032.
- Leading PARP Inhibitors companies such as TakaraBio, Merck, ShanghaiSunwayBiotech, SillaJen, and others are developing novel PARP Inhibitorss that can be available in the PARP Inhibitors market in the coming years.
- Some of the key PARP Inhibitorss include ZEJULA, AKEEGA, LYNPARZA, TALZENNA, RUBRACA, and others.
PARP Inhibitors Overview
PARP inhibitors are a class of drugs that target poly (ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair. These inhibitors have primarily been developed for the treatment of cancers, especially those associated with specific genetic mutations, such as BRCA1 and BRCA2 mutations.
PARP enzymes play a role in repairing damaged DNA. PARP inhibitors work by blocking these enzymes, preventing cancer cells from repairing their DNA effectively.
The concept of using PARP inhibitors is particularly relevant in cancers with deficiencies in the homologous recombination DNA repair pathway, such as those with BRCA mutations.
PARP enzymes play a role in repairing damaged DNA. PARP inhibitors work by blocking these enzymes, preventing cancer cells from repairing their DNA effectively.
The concept of using PARP inhibitors is particularly relevant in cancers with deficiencies in the homologous recombination DNA repair pathway, such as those with BRCA mutations.
PARP Inhibitors Treatment Market
The market for PARP inhibitors was experiencing growth, driven by their approvals for multiple cancer indications and ongoing research into their efficacy in various settings. However, the market dynamics may have evolved, and it’s recommended to check more recent sources for the latest information.
Competition among pharmaceutical companies played a role in shaping the market. New entrants, the development of combination therapies, and ongoing research contributed to the competitive landscape.
Access to PARP inhibitors, as well as pricing considerations, were factors influencing market growth. Discussions around the cost-effectiveness of these therapies, reimbursement policies, and patient access contributed to market dynamics.
The field of PARP inhibitors was dynamic, with ongoing research exploring new compounds, combination therapies, and applications in different stages of cancer treatment.
Learn more about the FDA-approved PARP Inhibitors @ PARP Inhibitors Drugs
Key PARP Inhibitors Therapies and Companies
- ZEJULA – GSK – Ovarian cancer, NSCLC, Endometrial cancer
- AKEEGA – JANSSEN BIOTECH – CRPC, HSPC
- LYNPARZA – AstraZeneca – Ovarian Cancer, Breast Cancer (HR+/HER2- and TNBC), Pancreatic Cancer, CRPC
- TALZENNA – Pfizer – Breast Cancer (HR+/HER2- and TNBC), CRPC, HSPC
- RUBRACA – Pharma& – Ovarian Cancer, CRPC
To know more about PARP Inhibitors clinical trials, visit @ PARP Inhibitors Treatment Drugs
|
PARP Inhibitors Report Metrics |
Details |
|
Study Period |
2019–2032 |
|
PARP Inhibitors Report Coverage |
7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
|
Key PARP Inhibitors Companies |
TakaraBio, Merck, ShanghaiSunwayBiotech, SillaJen, and others |
|
Key PARP Inhibitorss |
ZEJULA, AKEEGA, LYNPARZA, TALZENNA, RUBRACA, and others |
Scope of the PARP Inhibitors Market Report
- PARP Inhibitors Therapeutic Assessment: PARP Inhibitors current marketed and emerging therapies
- PARP Inhibitors Market Dynamics: Attribute Analysis of Emerging PARP Inhibitors Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, PARP Inhibitors Market Access and Reimbursement
Discover more about PARP Inhibitors drugs in development @ PARP Inhibitors Clinical Trials
Table of Contents
|
1. |
PARP Inhibitors Market Key Insights |
|
2. |
PARP Inhibitors Market Report Introduction |
|
3. |
PARP Inhibitors Market Overview at a Glance |
|
4. |
PARP Inhibitors Market Executive Summary |
|
5. |
Disease Background and Overview |
|
6. |
PARP Inhibitors Treatment and Management |
|
7. |
PARP Inhibitors Epidemiology and Patient Population |
|
8. |
Patient Journey |
|
9. |
PARP Inhibitors Marketed Drugs |
|
10. |
PARP Inhibitors Emerging Drugs |
|
11. |
Seven Major PARP Inhibitors Market Analysis |
|
12. |
PARP Inhibitors Market Outlook |
|
13. |
Potential of Current and Emerging Therapies |
|
14. |
KOL Views |
|
15. |
Unmet Needs |
|
16. |
SWOT Analysis |
|
17. |
Appendix |
|
18. |
DelveInsight Capabilities |
|
19. |
Disclaimer |
|
20. |
About DelveInsight |
Related Reports
KRAS Inhibitors Market
KRAS Inhibitors Market Insights, Epidemiology and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key KRAS inhibitors companies, including Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma, Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, among others.
JAK Inhibitors Competitive Landscape
JAK Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, among others.
TIGIT Inhibitors Competitive Landscape
TIGIT Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TIGIT inhibitors companies, including Merck Sharp & Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen, among others.
Checkpoint Inhibitors Competitive Landscape
Checkpoint Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key checkpoint inhibitors companies, including BeBetter Med, BIOCAD, CanBas Co., Ltd., Laekna Therapeutics, Genentech, Alphamab Oncology, Hangzhou Sumgen Biotech, Harbour BioMed, Aurigene Discovery Technologies, BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, among others.
PD-1 and PD-L1 Inhibitors Competitive Landscape
PD-1 and PD-L1 Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, among others.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/